Key result
Adjusted doses of low molecular weight heparin combined with peripartum human antithrombin III concentrate successfully prevented thromboembolic events and led to a healthy delivery in a pregnant woman with antithrombin deficiency and heparin resistance.
Case Report (n=1)
In pregnant women with congenital antithrombin deficiency, conventional LMWH doses may be inadequate due to heparin resistance, requiring dose adjustment and antithrombin III concentrate supplementation around delivery.
May support ATIII supplementation in heparin-resistant pregnant antithrombin deficiency; leaves open need for prospective trials.
BACKGROUND: The risk of thromboembolic events during pregnancy in patients with antithrombin deficiency is increased. Preventing thromboembolic events during pregnancy in the case of antithrombin deficiency is still a matter of concern. CASE PRESENTATION: We present a case of a 19-year-old primigravida Greek Pomak woman, who was diagnosed as having congenital antithrombin deficiency. She had a history of recurrent miscarriages and a family history of thrombosis. She was managed with adjusted doses of low molecular weight heparin throughout her pregnancy, with regular anti-Xa and antithrombin level monitoring. Prior to delivery and for 4 days after delivery she received human antithrombin III concentrate. She delivered a small for gestational age baby with no other complications. She required an increased dose of heparin due to heparin resistance. CONCLUSIONS: Antithrombin deficiency is associated with an increased risk of venous thromboembolic events with a 50% risk of thromboembolic events before the 50th year of life. It is a rare condition, so data concerning the optimal management during pregnancy are limited. The selection of patients who should receive low molecular weight heparin prophylaxis as well as dose intensity and monitoring are discussed. In our patient a conventional low molecular weight heparin dose proved to be inadequate at least at the laboratory level.
No takes yet. Share an insight, caveat, or question.
Tsikouras et al. (2018) conducted a case report in Congenital antithrombin deficiency in pregnancy (n=1). Low molecular weight heparin and human antithrombin III concentrate was evaluated on Maternal and fetal outcomes (thromboembolic events, bleeding, successful delivery). Adjusted doses of low molecular weight heparin combined with peripartum human antithrombin III concentrate successfully prevented thromboembolic events and led to a healthy delivery in a pregnant woman with antithrombin deficiency and heparin resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: